EGFR and colorectal carcinoma: Hence, one may hypothesize that the combination of GFHPD and anti-EGFR Ab therapy may be beneficial in low EGFR expressing CRC tumors, while the single GFHPD application may be efficacious in the therapy of RAS mutated CRC tumors.